CA2721025C - Thienopyridone derivatives as amp-activated protein kinase (ampk) activators - Google Patents

Thienopyridone derivatives as amp-activated protein kinase (ampk) activators Download PDF

Info

Publication number
CA2721025C
CA2721025C CA2721025A CA2721025A CA2721025C CA 2721025 C CA2721025 C CA 2721025C CA 2721025 A CA2721025 A CA 2721025A CA 2721025 A CA2721025 A CA 2721025A CA 2721025 C CA2721025 C CA 2721025C
Authority
CA
Canada
Prior art keywords
hydroxy
phenyl
pyridin
thieno
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2721025A
Other languages
English (en)
French (fr)
Other versions
CA2721025A1 (en
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Christine Charon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2721025(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2721025A1 publication Critical patent/CA2721025A1/en
Application granted granted Critical
Publication of CA2721025C publication Critical patent/CA2721025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2721025A 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators Active CA2721025C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290364 2008-04-11
EP08290364.2 2008-04-11
PCT/EP2009/001937 WO2009124636A1 (en) 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (2)

Publication Number Publication Date
CA2721025A1 CA2721025A1 (en) 2009-10-15
CA2721025C true CA2721025C (en) 2016-07-26

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721025A Active CA2721025C (en) 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Country Status (25)

Country Link
US (1) US8563729B2 (cg-RX-API-DMAC7.html)
EP (1) EP2262500B1 (cg-RX-API-DMAC7.html)
JP (1) JP5592348B2 (cg-RX-API-DMAC7.html)
KR (1) KR101630466B1 (cg-RX-API-DMAC7.html)
CN (1) CN101998853B (cg-RX-API-DMAC7.html)
AU (1) AU2009235784B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910439B8 (cg-RX-API-DMAC7.html)
CA (1) CA2721025C (cg-RX-API-DMAC7.html)
CO (1) CO6300954A2 (cg-RX-API-DMAC7.html)
DK (1) DK2262500T3 (cg-RX-API-DMAC7.html)
EA (1) EA017756B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010599A (cg-RX-API-DMAC7.html)
ES (1) ES2584278T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160907T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027857T2 (cg-RX-API-DMAC7.html)
IL (1) IL208067A (cg-RX-API-DMAC7.html)
MX (1) MX2010011047A (cg-RX-API-DMAC7.html)
MY (1) MY155836A (cg-RX-API-DMAC7.html)
NZ (1) NZ589136A (cg-RX-API-DMAC7.html)
PL (1) PL2262500T3 (cg-RX-API-DMAC7.html)
PT (1) PT2262500T (cg-RX-API-DMAC7.html)
SI (1) SI2262500T1 (cg-RX-API-DMAC7.html)
UA (1) UA103321C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009124636A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201008050B (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120549T1 (hr) * 2008-05-05 2012-07-31 Merck@Patent@GmbH Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk
DK2519527T3 (da) * 2009-12-29 2014-01-27 Poxel Thieno[2,3-b]pyridindion-aktivatorer af ampk og terapeutiske anvendelser deraf
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
MX2021005772A (es) * 2018-11-16 2021-10-13 Poxel Sal de monohidrato potasico de un derivado de tienopiridona y su proceso de preparacion.
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
AU2021244824A1 (en) 2020-03-26 2022-10-27 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
BR112022019403A2 (pt) * 2020-04-02 2022-12-06 Poxel Uso de um derivado de tienopiridona no tratamento de doença renal policística autossômica dominante (drpad)
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233641A (en) 1989-05-16 1992-07-28 Merrell Dow Pharma Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
CA2714181C (en) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators

Also Published As

Publication number Publication date
ZA201008050B (en) 2011-07-27
IL208067A (en) 2015-05-31
MY155836A (en) 2015-12-15
CA2721025A1 (en) 2009-10-15
IL208067A0 (en) 2010-12-30
JP5592348B2 (ja) 2014-09-17
MX2010011047A (es) 2010-10-26
US20110034505A1 (en) 2011-02-10
KR101630466B1 (ko) 2016-06-14
US8563729B2 (en) 2013-10-22
EP2262500A1 (en) 2010-12-22
HK1155955A1 (en) 2012-06-01
DK2262500T3 (en) 2016-08-15
SI2262500T1 (sl) 2016-09-30
EA201001585A1 (ru) 2011-06-30
BRPI0910439B1 (pt) 2020-10-20
CN101998853B (zh) 2015-02-11
ES2584278T3 (es) 2016-09-26
WO2009124636A1 (en) 2009-10-15
BRPI0910439B8 (pt) 2021-05-25
PT2262500T (pt) 2016-08-16
HRP20160907T1 (hr) 2016-09-23
HUE027857T2 (en) 2016-11-28
KR20100137563A (ko) 2010-12-30
EP2262500B1 (en) 2016-04-27
CO6300954A2 (es) 2011-07-21
AU2009235784A1 (en) 2009-10-15
AU2009235784B2 (en) 2013-09-19
NZ589136A (en) 2012-06-29
UA103321C2 (ru) 2013-10-10
PL2262500T3 (pl) 2016-09-30
JP2011516510A (ja) 2011-05-26
ECSP10010599A (es) 2010-12-30
CN101998853A (zh) 2011-03-30
EA017756B1 (ru) 2013-02-28
BRPI0910439A2 (pt) 2015-09-29

Similar Documents

Publication Publication Date Title
CA2721025C (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
CA2723429C (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
EP2285786B1 (en) Quinoxalinedione derivatives
EP2519527A1 (en) Thieno [2,3-b]pyridinedione activators of ampk and therapeutic uses thereof
HK1155955B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140314

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250922

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106